Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mercredi, novembre 18
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Tempest Therapeutics Inc
TPST
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.3500
0.0227
6.94%
Dern. MÀJ: Nov 18, 9:03 AM
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Rapport sur les stocks
Résultats:
Les résultats Q3 2026 ont été publiés le ven. nov. 13th, après la fermeture du marché
Tempest Therapeutics Financials
Tempest Therapeutics (TPST) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Tempest Therapeutics Q3 EPS $(0.21) Beats $(0.32) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.32) by 34.38 percent. This is a 73.42 percent increase over losses of $(0.79) per share
Benzinga Newsdesk
PRO
Tempest Therapeutics Q2 EPS $(0.34) Misses $(0.30) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 83.57 percent increase over losses of $(2.07) per
Benzinga Newsdesk
PRO
Tempest Therapeutics Q1 Adj. EPS $(0.50) Misses $(0.28) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.28) by 78.57 percent. This is a 84.18 percent increase over losses of $(3.16) per share
Benzinga Newsdesk
PRO
Tempest Therapeutics Q4 EPS $(0.62) Beats $(3.52) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(3.52) by 82.39 percent. This is a 87.77 percent increase over losses of $(5.07) per share
Benzinga Newsdesk
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results
Avi Kapoor
Nasdaq Gains Over 100 Points; Target Trims Earnings Forecast
Avi Kapoor